Kyverna Therapeutics (Kyverna Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Kyverna Therapeutics's net issuance of preferred for the three months ended in Mar. 2024 was $0.00 Mil. The number is 0, which means that Kyverna Therapeutics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Kyverna Therapeutics's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Kyverna Therapeutics Net Issuance of Preferred Stock Historical Data

The historical data trend for Kyverna Therapeutics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Net Issuance of Preferred Stock Chart

Kyverna Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

72.53

11.95

59.90

Kyverna Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial			-	-	-	-	-

Kyverna Therapeutics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Kyverna Therapeutics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, STE 550, Emeryville, CA, USA, 94608

Website

https://www.kyvernatx.com

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024